Simulations Plus Releases PKPlus™ Version 1.0 Next-Generation Software for Preclinical and Clinical Trial Data Analysis

Lancaster, CA—August 25, 2016—Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released version 1.0 of PKPlus, its next-generation software for analysis of preclinical and clinical trial data.

Mark Pflieger, product manager for PKPlus, said, “We have spent more than two years developing a true next-generation capability for two important types of analysis of preclinical and clinical trial results: noncompartmental analysis (NCA) and compartmental analysis (CA). Following from the PKPlus Module that has been in our GastroPlus™ software since 2000, this new standalone PKPlus was designed from the ground up around a relational database—Microsoft® SQL Server Express—to provide powerful new capabilities and a streamlined workflow that makes many analyses simple point-and-click operations. By eliminating the need to write code for equations, we simplified analyses and minimized errors, resulting in higher productivity and ease-of-use for analysts. Automatic and custom report generation is provided along with full audit trail and validation, which are required to assist companies in complying with 21 CFR Part 11 for their submissions to the U.S. Food and Drug Administration.”

John DiBella, vice president for marketing and sales for Simulations Plus, added, “Every lead compound that enters preclinical testing warrants some form of non-validated NCA, with promising candidates heading into clinical trials requiring validated NCA as part of the new drug applications submitted to regulatory agencies. CA is also often used to support submissions as well as to understand how various factors affect the absorption, distribution, and elimination of drugs from the body. PKPlus combines sophistication and simplicity, providing the capabilities to meet the needs of scientists across departments at pharmaceutical companies, contract research organizations (CROs), and other nonpharma markets, and with the value pricing and flexible licensing policies we have implemented, we believe it has the potential to become a significant contributor to revenues and earnings going forward.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said, “The PKPlus development team, consisting of scientists from both our Lancaster, California, and Buffalo, New York, divisions, has been working diligently to bring this new product to the industry for many months. The result is a testament to their dedication and hard work and is an excellent example of the continuously developing synergies between the two divisions.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed for and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at

Follow Us on Twitter.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995—With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market.

Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

For further information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA
93534-7059 USA

Simulations Plus Investor Relations
Ms. Renee Bouche

Hayden IR
Mr. Cameron Donahue